Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infeciton complications, genome and gene expression studies.
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Survival analysis, Cancer clinical trials, AIDS research and Sequential analysis. Studies include HPTN Statistical and Data Management Center—facilitates data collection, reporting, and statistical analysis for trials; manages HPTN study databases; guides protocol teams.
Elucidating cellular mechanisms for control of HIV replication, Assessing cellular immune responses in HIV vaccine recipients, Teaching and Mentoring Interests, HIV immunology for experts and the public
Determining how changes in microbial communities impact human health; identifying, characterizing, and culturing microbes found in the human genital tract; and associating the reproductive tract microbiome with human disease.
Developing molecular diagnostic tests to detect and identify pathogens in immunocompromised hosts such as cancer patients.
Research focus includes vaccine clinical trials, the design and analysis of Phase I/II trials, for evaluating vaccine effects on immune responses; the design and analysis of Phase 2b/III trials, for evaluating vaccine efficacy, immune correlates, sieve analysis, and post-infection vaccine effects; general biostatistical methods research, such as survival analysis, causal inference, and evaluation of surrogate endpoints
Developing methods and tools for high throughput, high dimensional experiments with applications in vaccine research and immunology; flow cytometry, peptide microarrays, next generation sequencing; Bayesian inference and computation and statistical computing
HIV vaccine trials; HIV prevention research: HIV vaccine, microbicide, biomedical and behavioral interventions, mother-to-child transmission of HIV and tuberculosis research in prevention and vaccine evaluation
Design, conduct, monitoring, and analysis of multicenter randomized clinical trials and comparative effectiveness studies, measuring and improving the effectiveness of informed consent in clinical research; improving the quality and efficiency of clinical trial data management; clinical research trials for the prevention or treatment of HIV / AIDS and vaccine clinical trials
Research focus included the design and evaluation of vaccine field trials; modeling infectious disease dynamics and strategies for mitigation and control; causal inference in infectious diseases; and evaluating surrogates of protection.
Research focus includes statistical methods for bioassays (e.g., flow cytometry, sequencing); dynamic modeling of biological systems (e.g., multi-type cell populations, B-cell repertoire); nonparametric methods for supervised and unsupervised learning; stochastic processes (e.g., branching processes); algorithms for scalable data analysis.
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
HIV and tuberculosis (Tb) vaccine research and development, human challenge experiments, microbiome modulation of immunity, immune activation—polymicrobial infections, combination HIV prevention, malaria clinical trials/vaccines and molecular epidemiology
Statistical support to clinical research on HSV1 and HSV2 and other herpesvirus infections; Clinical association between herpes and HIV; statistical methods work in areas such as misclassification in time-to-event outcomes, laboratory assay validation, and methods for quantifying and examining risk factors for viral shedding
Research focuses on development and application of novel methods for identifying and characterizing antigen specific T cells in the context of cancer and chronic infection with the goal of identifying specific and accurate biomarkers of human health and disease based on antigen-specific T cells.
Natural Killer Cell Receptor Diversity and CMV in Hematopoietic Cell Transplantation; Viral infections after Hematopoietic Stem Cell Transplantation; Epidemiology of invasive Fungal infections in Cord Blood Transplant Recipients and Clinical trials of the prevention of post-transplant infection
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication startegies, and to use models to capture kinetic features of the human microbiome.
Research is focused on the development of a safe and effective vaccine to combat the spread of HIV and to investigate how HIV infection leads to AIDS. Two major areas of research is to better understand how neutralizing antibodies against HIV are developed during natural HIV-infection,and engineer immunogens that will elicit broadly neutralizing antibody responses against HIV.
Research interests involve mechanisms driving the differentiation of B cells following vaccination and infection, understanding how differences in the pre-immune repertoire influences immunity and vaccine Development
Clinical focus is treating patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. Research is focused on cancer immunology, specifically the mechanisms and molecules that mediate graft-versus-host disease and graft-versus tumor.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.